Sunday, July 19, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient RivalstodayDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One4 weeks agoWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and MicrosofttodayDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money4 weeks agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and GrayscaletodayENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors4 weeks agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source LosestodayENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus4 weeks agoENERGYMichigan Renews Enbridge's Line 5 Tunnel Permit, Clearing a Key Hurdle for a Pipeline That Moves 540,000 Barrels a DayyesterdayDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI4 weeks agoENERGYMichigan Renews Enbridge's Line 5 Tunnel Permit, Removing the Biggest Regulatory Overhang on the Stock2 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive4 weeks agoTECHBosch's $225M CHIPS Award for Silicon Carbide Puts Wolfspeed and Onsemi on Notice2 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime4 weeks agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Open a New Revenue Line for Northrop and L3Harris2 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending4 weeks agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee-War Warning Shot for Bitwise and Grayscale2 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub4 weeks agoENERGYNew Mexico Blocks Oracle's Data Center Gas Pipeline, Exposing the Fragility of Big Tech's Power Build-Out2 days agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington4 weeks agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Hand a Direct Win to Directed-Energy Specialists3 days agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics4 weeks agoENERGYTrump's Nuclear Push Is Driving a Real Uranium Mining Revival — These Are the Stocks That Collect3 days agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction4 weeks agoWHITE HOUSEWhite House 'Gold Eagle' AI Cyber Clearinghouse Is a Direct Revenue Signal for CrowdStrike and Palantir3 days agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet4 weeks agoHEALTHCARE & FDACMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivals3 days agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos4 weeks agoDEFENSEJohnson's $95 Billion Defense Spending Plan Has Lockheed, RTX, and Northrop Written All Over It3 days agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys4 weeks agoWHITE HOUSETrump Shrinks Two Utah Monuments by 90%, Opening Land to Mining and Drilling3 days agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise4 weeks agoTRADE & TARIFFSPepsiCo's Tariff Refund Is a Small Win, But It Points to a Broader Cost Relief Story for Consumer Staples3 days agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story4 weeks agoDEFENSEThe UK's £300 Billion Defense Plan Is a Revenue Opportunity for U.S. Contractors — If They Can Win the Bids4 days agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift4 weeks agoENERGYPalisades Restart and Trump's Nuclear Push Are Turning Uranium Miners Into a Policy Trade4 days agoENERGYThe BLM Calendar That Moves COP and OXY4 weeks agoHEALTHCARE & FDAHHS Fraud Crackdown on Medicare Advantage Puts Managed Care Insurers and For-Profit Hospitals on Defense4 days agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through3 weeks agoMARKETSDOJ Kills TransDigm's $960M Deal — The Acquirer Takes the Hit, the Target Gets a Second Life5 days agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot3 weeks agoWHITE HOUSEESA 'Harm' Definition Rescinded — Extractive Industries Get Regulatory Relief, Conservation Stocks Face Uncertainty5 days agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly3 weeks agoENERGYPalisades Nuclear Restart and New SMR Plans Put Holtec — and Its Public Suppliers — in the Spotlight5 days agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently3 weeks agoDEFENSENATO Members Racing to 3.5% GDP Defense Spending — U.S. Contractors Are the Biggest Beneficiaries5 days agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil3 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Winners — and They're Already Public5 days agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly3 weeks agoCRYPTOThe CLARITY Act Could Redraw Crypto's Regulatory Map — Here's Which Public Names Win5 days agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes3 weeks agoTRADE & TARIFFSBIS Lifts Export Restrictions on UAE — Chip and Defense Tech Sellers Get a New Customer5 days agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program3 weeks agoCRYPTOVanguard's Crypto Pivot Signals Institutional Capitulation — Coinbase and Robinhood Are the Infrastructure Winners6 days agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for Lockheed, RTX, and Northrop6 days agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine3 weeks agoENERGYFederal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the Month6 days agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It3 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Stock Winners — and a Cryptography Deadline That Hurts Laggards6 days agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market6 days agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream3 weeks agoWHITE HOUSEFTC Forces Deere to Open Its Repair Tools — and Hands Independent Shops a Business Model6 days agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation3 weeks agoHEALTHCARE & FDAMedicare Advantage Plans Are Set to Collect $13 Billion in Quality Bonuses — UnitedHealth and Humana Lead the Queue6 days agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX3 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMD6 days agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Biggest Cost for SMR Developers6 days agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade3 weeks agoWHITE HOUSETrump's Subpoenas of NYT Reporters Create Legal Overhang for News Publishers — and a Tailwind for First Amendment Litigators6 days agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk3 weeks agoDEFENSENATO's Spending Surge Is Real and Getting Enforced — RTX, Lockheed, and AeroVironment Are the Direct Beneficiarieslast weekDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Marketlast weekDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending3 weeks agoENERGYUSDA's Revamped Biorefinery Loan Guarantee Program Is a Quiet Tailwind for ADM and Renewable Chemical Producerslast weekMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Clock for SMR Developerslast weekTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers3 weeks agoENERGYCommonwealth LNG Permit Moves Forward — Cheniere and ConocoPhillips Are Watching Closelylast weekTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch3 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDlast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock3 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Tools — Farmers Win, Deere's Software Moat Takes a Hitlast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever2 weeks agoCRYPTOThe SEC's 2026 Crypto Regulatory Agenda Is a Green Light for Coinbase and Robinhoodlast weekDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom2 weeks agoHEALTHCARE & FDATrump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed Signallast weekWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind2 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money2 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR Timelinelast weekMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech2 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry Winslast weekENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving2 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply Chainlast weekDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid2 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense Primeslast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone Awaylast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers2 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be Pricedlast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivals2 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct Beneficiarieslast weekWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stack2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risk2 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and Northroplast weekDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expense2 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sectorlast weekENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stocks2 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole Positionlast weekENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Win2 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lillylast weekCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling It2 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in Yearslast weekTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Means2 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBMlast weekWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiary2 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Callslast weekHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiarieslast weekHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payer2 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winnerslast weekTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immune2 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel Itlast weekDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spot2 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Tradelast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Playslast weekTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiaries2 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Story2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeuticslast weekENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Trade2 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paidlast weekHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers2 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Nameslast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment2 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Tradelast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironmentlast weekCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhoodlast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

CMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals

A proposed CMS rule targeting hospital payment premiums and 340B drug discounts puts large health systems on defense.

Image: Money Racket
By at Money Racket·Jul 19, 2026

CMS has proposed reforms that would push Medicare toward site-neutral payments — eliminating the premium hospitals charge for outpatient services performed in hospital-owned clinics versus independent physician offices — and would cut reimbursement rates under the 340B drug discount program, which reached $100 billion in sales in 2025.

Site-neutral payments would erase the billing premium that hospital-owned outpatient clinics have used to undercut independent rivals for years.

Who cashes in: Independent ambulatory surgery centers and physician-owned outpatient groups are the structural winners; they've long competed at a price disadvantage against hospital outpatient departments. Publicly traded ASC operators like Surgery Partners (SGRY) and United Surgical Partners (private, majority-owned by Tenet Healthcare THC) benefit as the payment gap narrows. On the 340B side, large pharmacy benefit managers and specialty pharmacies that sit outside the 340B program — including CVS Health CVS and Cigna/Evernorth (CI) — face less margin compression from 340B-subsidized competition.

Who's exposed: Large nonprofit and for-profit hospital systems are the direct losers. HCA Healthcare HCA, Tenet Healthcare THC, and Universal Health Services UHS all derive significant revenue from the outpatient premium that site-neutral rules would eliminate. Community health systems that rely heavily on 340B drug revenue — particularly safety-net hospitals — face a double hit. The American Hospital Association has already signaled legal challenges, so implementation is not guaranteed.

What to watch next: The comment period and any subsequent litigation will determine timing. Watch for HCA and Tenet management commentary on the magnitude of revenue at risk. If the rule survives legal challenge and is finalized, outpatient-focused operators like Surgery Partners could see a meaningful re-rating.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/cms-proposes-site-neutral-340b-cuts-hospital-pressure/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →